USS Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

USS Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-68,300	Closed	-$4.8M	–	560
2024 Q3	$4.8M	Buy	68,300 +4,209	+7%	+$352K	0.04%	411
2024 Q2	$5.28M	Buy	64,091 +3,086	+5%	+$257K	0.04%	364
2024 Q1	$5.33M	Buy	61,005 +4,259	+8%	+$381K	0.04%	367
2023 Q4	$5.47M	Sell	56,746 -5,429	-9%	-$480K	0.05%	343
2023 Q3	$5.5M	Buy	62,175 +9,730	+19%	+$866K	0.06%	335
2023 Q2	$4.55M	Hold	52,445	–	–	0.05%	378
2023 Q1	$5.1M	Hold	52,445	–	–	0.07%	327
2022 Q4	$5.43M	Hold	52,445	–	–	0.08%	309
2022 Q3	$4.45M	Sell	52,445 -8,415	-14%	-$749K	0.07%	330
2022 Q2	$5.04M	Sell	60,860 -2,641	-4%	-$210K	0.05%	375
2022 Q1	$4.9M	Buy	63,501 +16,364	+35%	+$1.37M	0.04%	450
2021 Q4	$4.17M	Hold	47,137	–	–	0.03%	486
2021 Q3	$3.64M	Sell	47,137 -576,049	-92%	-$45.5M	0.03%	514
2021 Q2	$52M	Hold	623,186	–	–	0.41%	62
2021 Q1	$47.1M	Hold	623,186	–	–	0.41%	64
2020 Q4	$54.6M	Buy	623,186 +3,500	+0.6%	+$277K	0.5%	58
2020 Q3	$47.1M	Hold	619,686	–	–	0.45%	57
2020 Q2	$76.4M	Sell	619,686 -196,917	-24%	-$19.6M	0.8%	30
2020 Q1	$69M	Sell	816,603 -361,859	-31%	-$31.2M	0.94%	35
2019 Q4	$99.6M	Buy	1,178,462 +443,462	+60%	+$33.5M	0.97%	40
2019 Q3	$49.5M	Hold	735,000	–	–	0.51%	47
2019 Q2	$63M	Hold	735,000	–	–	0.65%	45
2019 Q1	$65.3M	Hold	735,000	–	–	0.73%	40
2018 Q4	$62.7M	Sell	735,000 -35,000	-5%	-$3.33M	0.77%	43
2018 Q3	$74.7M	Sell	770,000 -340,000	-31%	-$33.9M	0.75%	44
2018 Q2	$105M	Sell	1,110,000 -229,671	-17%	-$20.1M	1.14%	38
2018 Q1	$112M	Buy	1,339,671 +249,738	+23%	+$21.4M	1.24%	35
2017 Q4	$97.2M	Hold	1,089,933	–	–	1.13%	36
2017 Q3	$101M	Hold	1,089,933	–	–	0.78%	37
2017 Q2	$99M	Buy	1,089,933 +743,599	+215%	+$67.7M	0.92%	28
2017 Q1	$30.4M	Hold	346,334	–	–	0.42%	65
2016 Q4	$28.7M	Hold	346,334	–	–	0.44%	61
2016 Q3	$32M	Hold	346,334	–	–	0.49%	58
2016 Q2	$26.9M	Hold	346,334	–	–	0.47%	59
2016 Q1	$28.6M	Hold	346,334	–	–	0.48%	59
2015 Q4	$36.3M	Sell	346,334 -118,000	-25%	-$12.3M	0.6%	58
2015 Q3	$48.9M	Sell	464,334 -50,000	-10%	-$6.68M	0.87%	50
2015 Q2	$70.4M	Sell	514,334 -225,000	-30%	-$27.9M	1.12%	40
2015 Q1	$92.1M	Hold	739,334	–	–	1.5%	29
2014 Q4	$66.8M	Hold	739,334	–	–	1.1%	43
2014 Q3	$53.4M	Hold	739,334	–	–	0.94%	55
2014 Q2	$46M	Hold	739,334	–	–	0.79%	55
2014 Q1	$50.4M	Hold	739,334	–	–	0.91%	57
2013 Q4	$51.1M	Sell	739,334 -74,000	-9%	-$5.03M	0.98%	49
2013 Q3	$58.7M	Hold	813,334	–	–	1.1%	49
2013 Q2	$45.3M	Buy	+813,334	New	+$50.7M	0.97%	54

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

USS Investment Management's BMRN Position: Q4 2024 in Review

USS Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 68,300 shares — an estimated $4.8M sold.

USS Investment Management first reported a position in BMRN in Q2 2013 and held it in 46 quarters. The position peaked at $112M in Q1 2018. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

USS Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
USS Investment Management sold 68,300 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $4.8M.
USS Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 46 quarters.
USS Investment Management's BioMarin Pharmaceuticals position peaked at $112M in Q1 2018.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on USS Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.